Neurovive: Topline Data Of Phase III Study Of CicloMulsion Expected This Quarter

(RTTNews) - NeuroVive Pharmaceutical AB (NEVPF.PK), the mitochondrial medicine company, said it expects to announce the topline result of the phase III CIRCUS study of CicloMulsion in patients with a specific type of heart attack known as ST-segment elevation acute myocardial infarction or STEMI this quarter due to an earlier than previously expected database lock.

The final results of the analysis of the 12-month data are expected in the third quarter 2015.

The company stated that topline result will provide baseline information on whether the primary endpoint has been met or not. The primary endpoint is a composite of three separate outcomes: mortality, hospitalizations for heart failure and left-ventricular remodeling.

The impact of these results on the future development of CicloMulsion will be communicated in the second half of 2015, NeuroVive said.